hormone

IGF-1 DES

FDA: research-only

IGF-1 DES is a short-acting splice variant of IGF-1 with strong affinity for injured tissues. It works best when injected directly into target muscle to promote localized growth and satellite cell proliferation, making it ideal for site-specific hypertrophy. Short half-life provides localized action on trained muscle. Strong affinity for injured tissues promotes targeted repair. Inhibits myostatin when combined with Follistatin-344. Activates satellite cell proliferation for site-specific muscle growth. More potent than LR3 for localized effects but shorter duration. - Localized muscle growth and hypertrophy - Post-session gains in target muscle groups - Sprint power enhancement - Site-specific tissue repair -

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight —

Half-life —

CAS number —

Route —

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE

IGF-1
Fasting Glucose
Fasting Insulin
CMP
CBC

DURING CYCLE

IGF-1
Fasting Glucose
Fasting Insulin

POST-CYCLE

IGF-1
Fasting Glucose

Safety & Regulatory Status

FDA STATUS research-only

Regulatory status for IGF-1 DES may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.